Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory effects of remimazolam in thoracoscopic lobectomy and impact on lung cancer cells
jRCT1031260170Recruiting
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of remimazolam in bronchial carcinoma and post-operative inflammation (2 arms), sponsored by none. Primary endpoint: Changes in inflammatory cytokines in plasma. Started Jun 2026; status: recruiting.
02
Drugs
remimazolam
03
Conditions
bronchial carcinomapost-operative inflammation
Beyond the preview
Go deeper on jRCT1031260170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260170.